K-Pio 15 mg

K-Pio 15 mg contains Pioglitazone 15 mg (as pioglitazone hydrochloride). Prescription required.

Type 2 diabetes mellitus to improve blood sugar control, as monotherapy or in combination with other antidiabetic medicines (e.g., metformin, sulfonylureas, insulin) along with diet and exercise

Pioglitazone is a thiazolidinedione that activates PPAR-γ receptors, increasing insulin sensitivity in adipose tissue, muscle and liver. It reduces insulin resistance, decreases hepatic glucose production and improves peripheral glucose uptake.

Oral tablet. Take exactly as prescribed, usually once daily at the same time each day, with or without food. Continue diet and exercise; monitor blood glucose regularly. Do not stop or change dose without medical advice.

Weight gain, edema (swelling), headache, dizziness, upper respiratory tract infection, muscle pain, diarrhea, increased appetite

Not for type 1 diabetes or diabetic ketoacidosis. Can cause or worsen heart failure—contraindicated in NYHA class III/IV; seek help for rapid weight gain, swelling or shortness of breath. Risk of fluid retention especially with insulin. Monitor liver function; avoid if active liver disease or significant ALT elevation. May increase risk of bone fractures (especially in women). Rare risk of macular edema—report vision changes. Use with caution in patients with history of bladder cancer or unexplained hematuria; assess risk/benefit. May cause ovulation in anovulatory women—use contraception if needed.

Insulin or other antidiabetics (increased risk of hypoglycemia/edema), gemfibrozil (increases pioglitazone levels), rifampicin (reduces pioglitazone levels), oral contraceptives (may reduce hormone levels), corticosteroids/NSAIDs (may increase fluid retention)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Pioz 15 Tablet, Pioglit 15 Tablet, Glitaz 15 Tablet, Piofine 15 Tablet, Piozone 15 Tablet